Measurement in saliva from neurotypical adults of biomarkers pertinent to autism spectrum disorders

Future Science OA

Volumn 1, Issue 4, 2015, Pages

  Ratajczak, Helen V ^a   Sothern, Robert B ^b  

^a Edmond Enterprises   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

autism; biomarkers; measurement; patient specific therapy; saliva

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLSEROTONIN METHYLTRANSFERASE; ALANINE; AMMONIA; BIOLOGICAL MARKER; CARNITINE; COMPLEMENT COMPONENT C4B; CYSTINE; GAMMA INTERFERON; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HYDROCORTISONE; INTERLEUKIN 12; MELATONIN; METALLOTHIONEIN; PRASTERONE; PROTEINASE INHIBITOR; SEROTONIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; AUTISM; CELL COUNT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SALIVA ANALYSIS; T LYMPHOCYTE;

EID: 85046042526     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fso.15.70     Document Type: Article

References (78)

1. Rosignol DA, Frye RE. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Front. Physiol. 5, 150 (2014).
2. Ratajczak HV. Theoretical aspects of autism: biomarkers -a review. J. Immunotox. 8(1), 80-94 (2011).
3. Jepson B. Changing the Course of Autism. Sentient Publications, Boulder CO, USA (2007).
4. Filipek PA, Juranek J, Nguyen MT, Cummings C, Gargus JJ. Relative carnitine deficiency in autism. J. Autism Dev. Disord. 34(6), 615-623 (2004).
5. Celestino-Soper PBS, Violante S, Crawford EL et al. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Proc. Natl Acad. Sci. USA 109(21), 7974-7981 (2012).
6. Frye RE, Rossignol DA. Treatments for biomedical abnormalities associated with autism spectrum disorder. Front. Pediatr. 2(66), 1-16 (2014).
7. Mostafa GA, AL-Ayadhi, . Reduced levels of plasma polyunsaturated fatty acids and serum carnitine in autistic children: relation to gastrointestinal manifestations. Behav. Brain Funct. 11(4), 1-10 (2015).
8. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J. Autism Dev. Disord. 31(6), 537-543 (2001).
9. Marrosu F, Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct. Neurol. 2(3), 355-361 (1987).
10. Cochrane DM, Sikoglu EM, Hodge SM et al. Relationship among glutamine, γ-aminobutyric acid, and social cognition in autism spectrum disorders. J. Child Adoles. Psychopharmacol. 25(4), 314-322 (2015).
11. Shanahan MR, Venturini AJ, Daiss JL et al. Peptide diagnostic markers for human disorders. European Patent Application, Ep 0 969 015 A2, 05 January 2000.
12. Bashir S, AL-Ayadhi L. Alterations in plasma dipeptidyl peptidase IV in autism: A pilot study. Neurol. Psychiat. Brain Res. 20(2), 41-44 (2014).
13. Cieslinska A, Sienkiewicz-Szlapka E, Wasilewska J et al. Influence of candidate polymorphisms on the dipeptidyl peptidase IV and μ-opiod receptor genes expression in aspect of the β- casomorphin-7 modulation functions in autism. Peptides 65, 6-11 (2015).
14. Cass H, Gringras P, March J et al. Absence of urinary opioid peptides in children with autism. Arch. Dis. Child. 93(9), 745-750 (2008).
15. Shattock P, Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin. Ther. Targets 6(2), 175-183 (2002).
16. Warren RP, Yonk J, Burger RW, Odell D, Warren WL. DR-positive T-cells in autism: Association with decreased plasma levels of the complement C4B protein. Neuropsychobiology 31(2), 53-57 (1995).
17. Warren RP, Singh VK, Cole P et al. Increased frequency of the null allele at the complement C4B locus in autism. Clin. Exp. Immunol. 83(3), 438-440 (1991).
18. Kunkel SL, Ward PA, Caporale LH, Vogel C-W. The complement system. In:Immunology III . Bellanti JA (Ed.). WB Saunders Co., PA, USA, 106-116 (1985).
19. Mostafa GA, Shehab AA. The link of C4B null allele to autism and to a family history of autoimmunity in Egyptian autistic children. J. Neuroimmunol. 223(1-2), 115-119 (2010).
20. Goines PE, Croen LA, Braunschweig D et al. Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Molec. Autism 2(13), 1-11 (2011).
21. Ibrahim S, El-Waleely T, Zakaria N, Ismail R. A study of serum interleukin-12 in a sample of autistic children in Egypt. Egyptian J. Psychiatry 36(2), 81-87 (2015).
22. Xu N, Li X, Zhong Y. Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders. Mediators Inflam. 2015, 1-10 (2015)
23. Curin JM, Terzic J, Petkovic ZB, Zekan L, Terzic IM, Susnjara IM. Lower cortisol and higher ACTH levels in individuals with autism. J. Autism Dev. Disord. 33(4), 443-448 (2003).
24. Selmaoui B, Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci. 73(26), 3339-3349 (2003).
25. Corbett BA, Mendoza S, Wegelin JA, Carmean V, Levine S. Variable cortisol circadian rhythms in children with autism and anticipatory stress. J. Psychiatry Neurosci. 33(3), 227-234 (2008).
26. Spratt EG, Nicholas JS, Brady KT et al. Enhanced cortisol response to stress in children in autism. J. Autism Dev. Disord. 42(1), 75-81 (2012).
27. Putnam SK, Lopata C, Thomeer ML, Volker MA, Rodgers JD. Salivary cortisol levels and diurnal patterns in children with autism spectrum disorder. J. Dev. Physical Disabil. 27(4), 453-465 (2015).
28. Corbett BA, Simon D. Adolescence, stress and cortisol in autism spectrum disorders. OA Autism 1(1), 1-6 (2013).
29. Melke J, Goubran-Botros H, Chaste P et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol. Psychiatry 13(1), 90-98 (2008).
30. Novakova M, Paclt I, Ptacek R, Kuzelova H, Hajek I, Sumova A. Salivary melatonin rhythm as a marker of the circadian system in healthy children and those with attention-deficit/hyperactivity disorder. Chronobiol. Int. 28(7), 630-637 (2011).
31. Sanchez de la Pena S. The feed-sideward of cephalo-adrenal immune interactions. Chronobiologia 20(1-2), 1-52 (1993).
32. Schwichtenberg AJ, Malow BA. Melatonin treatment in children with developmental disabilities. Sleep Med. Clin. 10(2), 181-187 (2015).
33. Tilford JM, Payakachat N, Kuhlthau KA et al. Treatment for sleep problems in children with autism and caregiver spillover effects. J. Autism Dev. Disord. doi:10.1007/ s10803-015-2507-5 (2015) (Epub ahead of print).
34. Belmonte MK, Cook Jr EH, Anderson GM et al. Autism as a disorder of neural information processing: directions for research and targets for therapy. Molec. Psychiatry 9(7), 646-663 (2004).
35. Whitaker-Azmitia PM. Behavioral and cellular consequences of increasing serotonergic activity during brain development. A role in autism? Int. J. Dev. Neurosci. 23(1), 75-83 (2005).
36. Adamsen D, Ramaekers V, Ho HTB et al. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Molec. Autism 5(43), 1-11 (2014).
37. Rose'Meyer R. A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders. Molec. Autism 4(37), 1-16 (2013).
38. Montoya ER, Terburg D, Bos PA, van Honk J. Testosterone, cortisol, and serotonin as key regulators of social aggression: A review and theoretical perspective. Motiv. Emot. 36, 65-73 (2012).
39. Takagishi H, Takahashi T, Inukai K et al. Salivary testosterone levels and autism-spectrum quotient in adults. Neuroendocrin. Let. 31(6), 101-105 (2010).
40. Baron-Cohen S, Auyeung B, Norgaard-Pedersen B et al. Elevated fetal steroidogenic activity in autism. Molec. Psychiatry 20, 369-376 (2015).
41. Auyeung B, Baron-Cohen S, Ashwin E, Knickmeyer R, Taylor K, Hackett G. Fetal testosterone and autistic traits. Br. J. Psychology 100, 1-22 (2009)
42. Baron-Cohen S. The extreme male brain theory of autism. Trends Cogn. Sci. 6(6), 248-254, (2002).
43. Krahn TM, Fenton A. The extreme male brain theory of autism and the potential adverse effects for boys and girls with autism. J. Bioeth. Inquiry 9(1), 93-103 (2012).
44. Larsen FV, Lai M-C, Wagner AP, MRC AIMS Consortium, Baron-Cohen S, Holland AJ. Testing the 'Extreme Female Brain' theory of psychosis in adults with autism spectrum disorder with or without co-morbid psychosis. PLOS ONE 10(6), e0128102. (2015).
45. Tordjman S, Anderson GM, McBride PA et al. Plasma androgens in autism. J. Autism Dev. Disord. 25(3), 295-304 (1995).
46. Majewska MD, Hill M, Urbanowicz E et al. Marked elevation of adrenal steroids, especially androgens, in saliva of prepubertal autistic children. Eur. Child Adolesc. Psychiatry 23, 485-498 (2014).
47. James SJ, Cutler P, Melnyk S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 80, 1611-1617 (2004).
48. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J. Nutr. 134, 489-492 (2004).
49. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm. Res. 66(4), 182-188 (2006).
50. Hansen RE, Roth D, Winther JR. Quantifying the global cellular thiol-disulfide status. Proc. Natl Acad. Sci. USA 106(2), 422-427 (2009).
51. Rose S, Melnyk S, Trusty TA et al. Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. Autism Res. Treat. 2012, 986519 (2012).
52. Walsh WJ, Usman A, Tarpey J. Disordered metal metabolism in a large autism population. Presented at: American Psychiatric Association Annual Meeting. New Orleans, LA, USA, 5-10 May 2001.
53. Obrenovich ME, Shamberger RJ, Lonsdale D. Altered heavy metals and transketolase found in autistic spectrum disorder. Biol. Trace Elem. Res. 144(1-3), 475-486 (2011).
54. Santos CRA, Martinho A, Quintela T, Goncalves I. Neuroprotective and neuroregenerative properties of metallothioneins. IUBMB Life 64(2), 126-135 (2012).
55. Pangborn JB. Nutritional Supplement Use for Autistic Spectrum Disorder. Autism Research Institute, CA, USA, 182 (2012).
56. Woods AG, Wetie AGN, Sokolowska I et al. Mass specterometry as a tool for studying autism spectrum disorder. J. Molec. Psychiatry 1(6), 1-10 (2013).
57. Wetie AGN, Wormwood KL, Russell S, Ryan JP, Carie CC, Woods AG. A pilot proteomic analysis of salivary biomarkers in autism spectrum disorder. Autism Res. 8(3), 338-350 (2015).
58. Wormwood KL, Aslebagh R, Channaveerappa D et al. Salivary proteomics and biomarkers in neurology and psychiatry. Proteomics Clin. Appl. doi:10.1002/ prca.201400153 (2015) (Epub ahead of print).
59. Rashid MH, Al-Jubouri RH. Assessment of serum and salivary oxidative stress biomarkers with evaluation of oral health status in a sample of autistic male children. J. Bagh College Dentistry 23(3), 56-60 (2011).
60. Monjan AA. Stress in immunologic competence: studies in animals. In:Psychoneuroimmunology. Ader R (Ed.). Academic Press, NY, USA, 185-228 (1981).
61. Corbett BA, Mendoza S, Abdullah M, Wegelin JA, Levine S. Cortisol circadian rhythms and response to stress in children with autism. Psychoneuroendocrinology 31(1), 59-68 (2006).
62. Sothern RB, Roitman-Johnson B. Biological rhythms and immune function. In:Psychoneuroimmunlogy Volume 1 (3rd Edition). Ader R, Felten DL, Cohen N (Eds). Academic Press, CA, USA, 445-449 (2001).
63. Sothern RB. Clinical medicine. In:Introducing Biological Rhythms. Koukkari WL, Sothern RB (Eds). Springer, NY, USA, 426-525 (2006).
64. Katrib K, Adlouni AH, Ferard G. Carnitine in human polymorphonuclear leukocytes, mononuclear cells, and platelets. Am. J. Clin. Nutr. 46, 734-735 (1987).
65. Gleeson M. Dosing and efficacy of glutamine supplementation in human exercise and sport training. J. Nutr. 138(10), S2045-S2049 (2008).
66. Stegink LD, Filer LJ Jr, Baker GL. Plasma amino acid concentrations in normal adults fed meals with added monosodium L-glutamate and aspartame. J. Nutr. 113, 1851-1860 (1983).
67. Schmidt D, Loscher W. Plasma and cerebrospinal fluid γ-aminobutyric acid in neurological disorders. J. Neurol. Neurosurg. Psychiatry 45(10), 931-935 (1982).
68. Songok EM, Osero B, Mckinnon L et al. CD26/dipeptidyl peptidase IV (CD26/DPPIV) is highly expressed in peripheral blood of HIV-1 exposed uninfected female sex workers, Virol. J. 7, 343-349 (2010).
69. Hammond A, Ollier W, Walport MJ. Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B. Clin. Exp. Immunol. 88(1), 153-168 (1992).
70. Chodorowska G. Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment. J. Eur. Acad. Dermatol. Venereology 10(2), 147-151 (1998).
71. Wu HP, Shih CC, Lin CY, Hua CC, Chuang DY. Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors. 10(2), 147-151 (1998).
72. Villette JM, Bourin P, Doinel C et al. Circadian variations in plasma levels of hypophyseal adrenocortical and testicular hormones in men infected with human immunodeficiency virus. J. Clin. Endocrinol. Metab. 70(3), 572-577 (1990).
73. Rao ML, Gross G, Strebel B et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol. Psychiatry 35(3), 151-163 (1994).
74. Brigham MP, Stein WH, Moore S. The concentrations of cysteine and cystine in human blood plasma. J. Clin. Invest. 39(110, 1633-1638 (1960).
75. Jones DP, Carlson JL, Samiec PS et al. Glutathione measurement in human plasma. Evaluation of sample collection, storage and derivatization conditions for analysis of dansyl derivatives by HPLC. Clin. Chim. Acta 275(2), 175-184 (1998).
76. Milnerowicz H, Bizon A. Determination of metallothionein in biological fluids using enzyme-linked immunoassay with commercial antibody. Acta Biochim. Polonica 57(10), 99-104 (2010).
77. Xie H, Onsongo G, Popko J et al. Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol. Cell. Proteomics 7(3), 486-498 (2008).
78. Brandtzaeg P. Salivary immunoglobulins. In:Human Saliva : Clinical Chemistsry and Microbiology (Volume II). Tenovuo JO (Ed.).CRC Press Inc., FL, USA, 3-11(1989).